Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Virology. 2014 Nov 21;475:1–14. doi: 10.1016/j.virol.2014.10.035

Figure 3. Antiviral effects of compounds on attenuated VSV-CT9-M51 and tumor-adapted VSV-rp30.

Figure 3

A) Representative fluorescence and phase contrast photomicrographs of primary adult human glia cultures infected with VSV-CT9-M51 (left panel) or VSV-rp30 (right panel). Ribavirin preincubation completely protected the cultures from viral infection. MPA protected from VSV-CT9-M51 infection with little effect on VSV-rp30 infection. Rimantadine had no protective effect. Scale bar 100 μm. B) Graphs displaying viability rates of normal embryonic human astrocytes infected with VSV-CT9-M51 (left) or VSV-rp30 (right) at MOI 0.1 using MTT viability after incubation with compounds at low or high drug concentration respectively.